Cancer immunotherapies
by design™
iTeos Therapeutics is pioneering the discovery and development of highly differentiated immuno-oncology therapeutics for patients.
At iTeos, we specialize in targeted immunotherapies for people living with cancer.
We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies.
Our two clinical stage programs, EOS-448 and Inupadenant, were designed with the aim of having best-in-class properties. We are moving rapidly into late stage clinical trials to explore the full potential of our science.
As a responsible company, we are committed to building Environmental, Social and Governance (ESG) principles into how we operate to create sustainable value for society and all of our stakeholders.
Our pipeline
Our efforts are targeting various cancer indications using our drug candidates either in monotherapy or in combination with additional drugs, as well as in intraportfolio combinations.
The following information provides an overview of our dynamic pipeline of cancer therapy development. Studies underway are grouped by our primary drug therapies, and listed out by combination with other treatments. Indications for each combination under study, along with the current and planned phases of each study, are included.
iTeos drug trials move through five phases:
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
iTeos drug trials move through five phases:
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
EOS-448
Following is a list of drug combinations currently under study with EOS-448, as well as the indication for each.
drug combo and indication:
+ dostarlimab | 1L NSCLC PDL1high
status of study phases:
Phase 2, active
drug combo and indication:
+ dostarlimab | 1L HNSCC PDL1high / low
status of study phases:
Phase 2, active
drug combo and indication:
+ dostarlimab + CD96 | Advanced Malignancies
status of study phases:
Phase 1, active
drug combo and indication:
+ dostarlimab + Inupadenant | Advanced Malignancies
status of study phases:
Phase 1, planned
drug combo and indication:
+ Inupadenant | Advanced Malignancies
status of study phases:
Phase 2, active
drug combo and indication:
Monotherapy/+ iberdomide | Relapsed Refractory Multiple Myeloma
status of study phases:
Phase 2, active
Inupadenant
Following is a list of drug combinations currently under study with Inupadenant, as well as the indication for each.
drug combo and indication:
Monotherapy | High Biomarker
status of study phases:
Phase 2, active
drug combo and indication:
+ pembrolizumab | PD-1 Resistant Melanoma
status of study phases:
Phase 2, active
drug combo and indication:
+ chemotherapy | 2L Chemo-naive NSCLC
status of study phases:
Phase 2, active
EOS-984
Following is a list of drug combinations currently under study with EOS-984, as well as the indication for each.
drug combo and indication:
IND Enabling Studies
status of study phases:
Preclinical, active
Studies with dark backgrounds are active. Studies with light backgrounds are planned.
There has never been a better time to work at iTeos.
As a leading clinical-stage biotech, our innovative science-driven work is fascinating and potentially lifesaving.
Whether it is working in our laboratory or in our offices, you will help people live healthier lives. You will find yourself on the forefront of science, within a high-tech environment where no two days are the same.
Latest press releases
iTeos to Present at the Piper Sandler 34th Annual Healthcare Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 22, 2022 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company…
iTeos Reports Third Quarter 2022 Financial Results and Provides Business Updates
– Initiated a randomized Phase 2 trial evaluating anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and GSK’s anti-PD-1 Jemperli (dostarlimab) in first line, metastatic…
